Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation

Import and Export of Misfolded α-Synuclein

(2018) Lilia Rodriguez et al.   Frontiers in Neuroscience

Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies

(2018) Ian F. Caplan et al.   Frontiers in Pharmacology

Therapeutic approaches to target alpha-synuclein pathology

(2017) Patrik Brundin et al.   EXPERIMENTAL NEUROLOGY

Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy

(2017) Omar El-Agnaf et al.   NEUROBIOLOGY OF DISEASE

Single nucleotide polymorphisms in the toll-like receptor 2 (TLR2) gene are associated with sporadic Parkinson’s disease in the North-eastern Han Chinese population

(2017) Xiaoyuan Li et al.   NEUROSCIENCE LETTERS

Pathological α-synuclein exacerbates the progression of Parkinson’s disease through microglial activation

(2017) Qiu-Shuang Zhang et al.   TOXICOLOGY LETTERS

Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy

(2017) Elvira Valera et al.   Acta Neuropathologica Communications

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy

(2017) Brian Spencer et al.   Acta Neuropathologica Communications

Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology

(2016) Nicolas Dzamko et al.   ACTA NEUROPATHOLOGICA

Ade novocompound targeting α-synuclein improves deficits in models of Parkinson’s disease

(2016) Wolfgang Wrasidlo et al.   BRAIN

Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer’s disease

(2016) Claire L. McDonald et al.   BRAIN BEHAVIOR AND IMMUNITY

Cellular Uptake of α-Synuclein Oligomer-Selective Antibodies is Enhanced by the Extracellular Presence of α-Synuclein and Mediated via Fcγ Receptors

(2016) Gabriel Gustafsson et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease

(2016) Katherine E Olson et al.   CURRENT OPINION IN PHARMACOLOGY

Proteolysis of α-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology

(2016) Amanda N. Sacino et al.   JOURNAL OF NEUROCHEMISTRY

α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology

(2016) Josefine R. Christiansen et al.   Journal of Neuroinflammation

Glia and alpha-synuclein in neurodegeneration: A complex interaction

(2016) Dominik Brück et al.   NEUROBIOLOGY OF DISEASE

Pathological  -synuclein transmission initiated by binding lymphocyte-activation gene 3

(2016) X. Mao et al.   SCIENCE

Alpha-Synuclein Oligomers—Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders

(2016) Martin Ingelsson   Frontiers in Neuroscience

α -synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease

(2016) Brian Spencer et al.   Annals of Clinical and Translational Neurology

Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson’s disease

(2015) Changyoun Kim et al.   Journal of Neuroinflammation

Active immunization therapies for Parkinson's disease and multiple system atrophy

(2015) Achim Schneeberger et al.   MOVEMENT DISORDERS

Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders

(2015) Elvira Valera et al.   Neurotherapeutics

Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy

(2015) Changyoun Kim et al.   Cell Reports

Toll-Like Receptor Expression in the Blood and Brain of Patients and a Mouse Model of Parkinson's Disease

(2015) J. Drouin-Ouellet et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Anti-Human α-Synuclein N-Terminal Peptide Antibody Protects against Dopaminergic Cell Death and Ameliorates Behavioral Deficits in an AAV-α-Synuclein Rat Model of Parkinson’s Disease

(2015) Md Shahaduzzaman et al.   PLoS One

Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials

(2014) Markus Mandler et al.   ACTA NEUROPATHOLOGICA

Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models

(2014) D. Games et al.   JOURNAL OF NEUROSCIENCE

Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5 – implications for dementia with Lewy bodies

(2014) Cassia R Overk et al.   Molecular Neurodegeneration

ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo

(2014) Brian Spencer et al.   MOLECULAR THERAPY

Extracellular α-synuclein—a novel and crucial factor in Lewy body diseases

(2014) He-Jin Lee et al.   Nature Reviews Neurology

Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein

(2014) Eun-Jin Bae et al.   Nature Communications

α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration

(2014) Hien T. Tran et al.   Cell Reports

Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice

(2013) Franz Marxreiter et al.   NEUROBIOLOGY OF DISEASE

Extracellular Regulated Kinase 1/2 Signaling Is a Critical Regulator of Interleukin-1β-Mediated Astrocyte Tissue Inhibitor of Metalloproteinase-1 Expression

(2013) Jerel Fields et al.   PLoS One

Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia

(2013) Changyoun Kim et al.   Nature Communications

Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor

(2012) Ruben J. Boado et al.   BIOTECHNOLOGY AND BIOENGINEERING

The many faces of α-synuclein: from structure and toxicity to therapeutic target

(2012) Hilal A. Lashuel et al.   NATURE REVIEWS NEUROSCIENCE

A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice

(2012) Marie-Francoise Chesselet et al.   Neurotherapeutics

Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts

(2011) Lisa Fellner et al.   ACTA NEUROPATHOLOGICA

Glia: Initiators and progressors of pathology in Parkinson's disease

(2011) Glenda M. Halliday et al.   MOVEMENT DISORDERS

Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease

(2011) Eliezer Masliah et al.   PLoS One

New Therapeutic Strategy for Parkinsons and Alzheimers Disease

(2010) E. Esposito et al.   CURRENT MEDICINAL CHEMISTRY

Lysosomal Degradation of α-Synucleinin Vivo

(2010) Sally K. Mak et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Direct Transfer of α-Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies

(2010) He-Jin Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Alpha-Synuclein Stimulation of Astrocytes: Potential Role for Neuroinflammation and Neuroprotection

(2010) He-Jin Lee et al.   Oxidative Medicine and Cellular Longevity

Toll-like receptors in control of immunological autophagy

(2009) M A Delgado et al.   CELL DEATH AND DIFFERENTIATION

Clearance and deposition of extracellular α-synuclein aggregates in microglia

(2008) He-Jin Lee et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Wild Type α-Synuclein Is Degraded by Chaperone-mediated Autophagy and Macroautophagy in Neuronal Cells

(2008) Tereza Vogiatzi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Controlling the mass action of α-synuclein in Parkinson’s disease

(2008) Changyoun Kim et al.   JOURNAL OF NEUROCHEMISTRY